Plasma cell myeloma

8 trials 3 recruiting MedDRA PT
8 Registered trials
3 Recruiting
4 Unique sponsors
16 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
H Endocrinology (ATC H) 5
L Oncology (ATC L) 5
J Anti-infectives (ATC J) 2
Mechanism of action (INN-stem analysis)
Corticosteroid 4 substances
Proteasome inhibitor 2 substances
IMiD 2 substances
Monoclonal antibody (rat) 2 substances
Monoclonal antibody (immune) 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Immunoglobulin 1 substance
Monoclonal antibody (human) 1 substance
Unknown / small molecule 1 substance
Phase III: 4 Phase II: 1 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

4 trials
  • Janssen - Cilag International Commercial
    BORTEZOMIB; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; ELOTUZUMAB; HUMAN NORMAL IMMUNOGLOBULIN; POMALIDOMIDE; TALQUETAMAB; TECLISTAMAB
    2022-502446-27-00 13 countries 2024 n=470 Orphan
    Ended
  • Janssen - Cilag International Commercial
    DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; HUMAN NORMAL IMMUNOGLOBULIN; POMALIDOMIDE; TALQUETAMAB
    2023-503467-41-00 9 countries 2022 n=310 Orphan
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.; ISATUXIMAB; LENALIDOMIDE
    2023-507419-37-00 11 countries 2020 n=272
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    BORTEZOMIB; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.; ISATUXIMAB; LENALIDOMIDE
    2024-514417-34-00 11 countries 2017 n=308
    Ended

Phase II

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    CARFILZOMIB; CEMIPLIMAB; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.; ISATUXIMAB; LENALIDOMIDE; POMALIDOMIDE
    2023-507180-19-00 7 countries 2023 n=37 Orphan
    Ended

Phase I/II

1 trial
  • Cellcentric Limited Commercial
    INOBRODIB
    2024-519498-20-00 1 country 2025 n=16
    Recruiting

Phase I

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506993-11-00 1 country 2023 n=22
    Recruiting

Phase I (Other)

1 trial
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-515316-44-00 2 countries 2025 n=32
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 3 Phase I (Other), Phase III 1
Sanofi-Aventis Recherche & Developpement Commercial 3 Phase II, Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 1
Cellcentric Limited Commercial 1 Phase I/II 1
New trials by year
2020
1
2022
1
2023
2
2024
1
2025
2
← All indication landscapes